Test Price
850 AED✅ Home Collection Available
NAFLD Genetic Susceptibility Panel (PNPLA3 & TM6SF2 Genotyping) in UAE | 850 AED
Executive Summary & Core Metrics
This advanced genetic panel directly targets the PNPLA3 (I148M) and TM6SF2 (E167K) polymorphisms, the two most validated risk alleles for non‑alcoholic fatty liver disease (NAFLD), non‑alcoholic steatohepatitis (NASH), and fibrosis progression. Conducted via real‑time PCR with Sanger confirmation under ISO 9001:2015‑certified protocols, our 850 AED test provides definitive genotyping from a single blood draw with VIP home collection available. Every report includes a clinical interpretation call with a DHA‑licensed specialist and supports proactive, precision‑driven liver health management.
Test Overview & Methodology
This genotyping test screens for the PNPLA3 rs738409 (I148M) and TM6SF2 rs58542926 (E167K) variants—genetic markers independently associated with a 3–5 fold increased risk of progressive NAFLD and hepatocellular carcinoma. By identifying high‑risk genotypes early, you and your physician can implement aggressive lifestyle modifications, pharmaconutritional interventions, and scheduled surveillance imaging long before irreversible fibrosis sets in.
| Feature | Our Test | Closest Alternative (Standard Liver Profile) |
|---|---|---|
| Precision | >99.9% sensitivity via qPCR + Sanger confirmation | ALT/AST only – no genetic risk quantification |
| Methodology | Real‑time PCR with allele‑specific probes, Sanger‑validated | Colorimetric/ enzymatic assays |
| Turnaround | Sample Mon/Thu by 9 AM → Report Wed/Sat | Often 24–48h; no genetic insight |
| Home Collection | 8 AM‑11 PM, all Emirates, cold‑chain transport | May require clinic visit |
| Post‑Test Support | Telephonic clinical guidance included | Often limited to automated report |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh – Consultant Medical Genetics (DHA Registration ID: 9294403) shares a direct clinical perspective:
“The PNPLA3 and TM6SF2 genotypes offer robust risk stratification for progressive NAFLD, yet they must be integrated with clinical parameters such as liver enzymes, metabolic profile, and imaging findings. A favourable genotype does not preclude NAFLD from lifestyle factors, nor does a high‑risk genotype guarantee advanced disease. This panel empowers patients to engage in targeted preventive care—use it as a catalyst for sustained behavioural change rather than a deterministic label.”
Important Advisory
⛔ Medication & Clinical Precautions
Do not discontinue any prescribed medication without prior consultation with your treating physician. Results from this genetic panel are intended to complement, not replace, your ongoing clinical management plan.
- Patients on anticoagulants must consult their physician prior to blood draw – minor bleeding risk.
- Not recommended for individuals with active hepatic decompensation or acute liver failure.
- Genetic testing for minors requires explicit parental consent and documented clinical necessity under Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Exclusion Criteria & Emergency Red Flags
Emergency Red Flags:
If you experience sudden severe right upper quadrant pain, jaundice, or confusion, proceed to the nearest emergency department immediately – do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. What does the PNPLA3 & TM6SF2 genetic panel detect, and how can it influence my liver health plan?
This panel identifies the two strongest inherited risk variants for progressive NAFLD, enabling your gastroenterologist to classify your predisposition into low‑, moderate‑, or high‑risk categories. A high‑risk genotype may prompt earlier imaging, targeted nutrigenomic advice, and more frequent liver enzyme monitoring, while a normal result provides reassurance and focus on modifiable factors.
2. Is home blood collection available across all Emirates, and how do I prepare?
Yes, our DHA‑licensed phlebotomists provide cold‑chain home collection in Dubai, Abu Dhabi, Sharjah, and all Emirates from 8 AM–11 PM. Please fast for 4 hours and hydrate well before collection. A Genomics Clinical Information Requisition Form (Form 20) must be completed before the visit; we send it electronically. The sample is drawn into a lavender‑top EDTA tube and transported refrigerated to our central lab within 4 hours.
3. Will my genetic data remain confidential under UAE law?
Your DNA information is protected under Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All sequencing data are anonymized after reporting, stored on UAE‑based servers compliant with ISO 27001, and only accessible to you and the ordering physician with explicit consent. No genetic information is used for any purpose other than your clinical care.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates in full compliance with the UAE healthcare and data protection framework. Your personal and genetic information is safeguarded under Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring patient consent, safety, and professional accountability. Our laboratory is DHA‑licensed (Facility License No. 1143) and maintains ISO 9001:2015 certification for quality management.
Clinical & Logistical Metadata
| Test Name | NAFLD Genetic Susceptibility Panel (PNPLA3 & TM6SF2 Genotyping) |
| Price (AED) | 850 AED |
| Turnaround Time | Sample Mon/Thu by 9 AM → Report Wed/Sat (3–4 business days) |
| Sample Type / Matrix | Peripheral whole blood (lavender‑top EDTA tube) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Real‑time PCR with allele‑specific probes, Sanger confirmation |
| ICD-10-CM Code | Z13.89 (Encounter for screening for other disorder), Z15.09 (Genetic susceptibility to other malignant neoplasm), K76.0 (Fatty liver, not elsewhere classified) |
| LOINC Code | 78051-5 (PNPLA3 gene mutation analysis) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians